Congressional Budget Office Cost Estimate: Estimated Budgetary Effects of H.R. 2891, the Preserve Access to Affordable Generics and Biosimilars Act [open pdf - 176KB]
From the Document: "Under H.R. 2891, certain agreements that are used to settle claims of patent infringement between sponsors of brand-name, generic, or biosimilar drugs and relating to the sale of a drug or biological product would presumptively be considered illegal under antitrust law. Based on discussions with drug industry experts, CBO [Congressional Budget Office] expects that the bill would accelerate the availability of lower-priced generic or biosimilar drugs that would be affected by such agreements. The estimated budgetary effects would stem from lower average prices for federal health programs that purchase prescription drugs and lower costs of health insurance subsidies. The areas of significant uncertainty for this estimate include CBO's estimates of sales, market effects, and timing of introductions of new pharmaceutical products. CBO has not completed an estimate of the effects of H.R. 2891 on spending subject to appropriation."
Congressional Budget Office: http://www.cbo.gov/